Sanofi (NYSE:SNY) gapped up before the market opened on Wednesday . The stock had previously closed at $40.88, but opened at $41.19. Sanofi shares last traded at $41.80, with a volume of 442,669 shares changing hands.

Several equities research analysts recently issued reports on SNY shares. Chardan Capital reissued a “buy” rating on shares of Sanofi in a research report on Tuesday, April 12th. Zacks Investment Research raised Sanofi from a “hold” rating to a “buy” rating and set a $48.00 price target on the stock in a research report on Thursday, April 7th. Bank of America Corp. reissued a “buy” rating and set a $58.00 price target on shares of Sanofi in a research report on Tuesday, May 3rd. HSBC lowered Sanofi from a “buy” rating to a “hold” rating in a research report on Tuesday, May 3rd. Finally, Citigroup Inc. reissued a “neutral” rating on shares of Sanofi in a research report on Tuesday, June 28th. Four equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and four have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $49.67.

The firm has a market capitalization of $107.95 billion and a P/E ratio of 22.81. The stock has a 50-day moving average of $40.62 and a 200-day moving average of $40.69.

A number of hedge funds and institutional investors recently made changes to their positions in the company. Morgan Stanley raised its position in shares of Sanofi by 34.9% in the fourth quarter. Morgan Stanley now owns 3,660,972 shares of the company’s stock valued at $156,140,000 after buying an additional 946,483 shares during the period. Seminole Management Co. Inc. bought a new position in shares of Sanofi during the fourth quarter valued at about $26,208,000. Haverford Trust Co. raised its position in shares of Sanofi by 3.5% in the fourth quarter. Haverford Trust Co. now owns 500,192 shares of the company’s stock valued at $21,333,000 after buying an additional 16,855 shares during the period. Bank of Montreal Can raised its position in shares of Sanofi by 0.7% in the fourth quarter. Bank of Montreal Can now owns 389,519 shares of the company’s stock valued at $16,614,000 after buying an additional 2,560 shares during the period. Finally, Tekla Capital Management LLC bought a new position in shares of Sanofi during the fourth quarter valued at about $13,008,000.

Sanofi SA is a healthcare company focused on patient needs and engaged in the research, development, manufacture and marketing of healthcare products. The Company is organized around three principal activities: Pharmaceuticals, Human Vaccines via Sanofi Pasteur, and Animal Health via Merial. The Company invests in emerging markets, diabetes solutions, vaccines, consumer health care, animal health, genzyme and other products.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.